Case Report: BKV-specific T cells: a fast, safe and potentially effective treatment option for refractory BKV infections in pediatric patients after allogeneic stem cell transplantation - Summary - MDSpire
Advertisement
Case Report: BKV-specific T cells: a fast, safe and potentially effective treatment option for refractory BKV infections in pediatric patients after allogeneic stem cell transplantation
To assess the feasibility, safety, and effectiveness of BKV-specific T cells in pediatric patients with refractory BKV infections post-allogeneic stem cell transplantation, emphasizing the need for innovative treatments.
Key Findings:
Three out of four patients showed a decrease in BKV viral load after T-cell adoptive transfer, with specific metrics indicating the extent of reduction.
Measurable in vivo expansion of BKV-specific T cells was observed in these patients.
The treatment was well tolerated with no infusion-related adverse effects or severe de novo graft-versus-host disease.
Interpretation:
Rapidly produced BKV-specific T cells may provide a feasible and safe treatment alternative for refractory BKV infections, with potential for improved efficacy when administered promptly and with limited immunosuppression, highlighting the importance of timing.
Limitations:
Complete viral eradication was not achieved in all patients, which may impact long-term outcomes.
One patient with significant immunosuppression showed minimal viral response and no detectable BKV-specific T cells post-infusion, indicating the need for tailored approaches.
Conclusion:
BKV-specific T cell therapy represents a promising approach for managing refractory BKV infections in pediatric patients post-transplant, warranting further investigation to confirm these findings and explore broader applications.
In the management of stage I testicular cancer, a persistent clinical dilemma is the identification of patients who truly need adjuvant treatment after orchiectomy rather than active surveillance alon...
Despite compelling prognostic associations across multiple retrospective data sets, no interventional trial has demonstrated that acting on circulating tumor DNA testing results in early breast cancer...
